Runbo

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Runbo

Quick Facts

Property Description
Active Ingredient Sodium Cromoglycate (Cromolyn Sodium)
Pharmacological Class Mast Cell Stabilizer, Antiallergic
Common Use Prophylactic (Preventive) Management
Origin Synthetic Compound (Chromone Derivative)
Forms Ophthalmic, Nasal, Inhalation, Oral Solution

Runbo: Active Ingredient, Origin, and Type

Runbo is a pharmaceutical product defined by its sole active component, Sodium Cromoglycate, also widely known by the generic name Cromolyn Sodium. This chemical entity is a synthetic compound derived from the chromone class of molecules, confirming its origin via chemical synthesis rather than direct natural extraction. The drug’s composition is that of a single-ingredient product (monotherapy), where the Sodium Cromoglycate is formulated predominantly in an aqueous base or appropriate pharmaceutical excipients, supporting its use for localized delivery.

Pharmacological Classification and General Purpose

The medicine belongs to the definitive mast cell stabilizer pharmacological class, a category clinically recognized for its anti-allergic properties. This functional classification is based on its ability to inhibit the sudden bursting, or degranulation, of mast cells, thereby preventing the release of primary inflammatory chemicals such as histamine and leukotrienes. Runbo's overall therapeutic purpose is strictly prophylaxis, or prevention, classifying it as an antiallergic and antiasthmatic agent. This compound is used globally for the prophylaxis of allergic conditions, reinforcing its role as a key preventive measure.

Forms and Administration Types

Sodium Cromoglycate is manufactured in specific dosage forms tailored for localized action against allergic inflammation. These forms include an ophthalmic solution (eye drops), a nasal solution (spray), a solution for nebulisation (inhalation), and an oral solution concentrate. This range of preparations facilitates drug delivery via ocular, nasal, pulmonary, and oral routes, corresponding directly to the targeted site where the prophylactic effect is required.

Regulatory References

  1. National Library of Medicine
  2. WHO Essential Medicines

What side effects are possible with Runbo?

Possible Side Effects and Safety Information

The full safety profile, including frequency classifications for adverse drug reactions (ADRs) and detailed warnings, is not available from major governmental regulatory bodies (such as the FDA or EMA) under the drug name Runbo.

Authoritative regulatory documentation is the standard basis for all safety information. In the absence of an official regulatory label, the following points summarize the current status of the known safety structure.


Adverse Reaction Scope

Category Regulatory Status (Runbo)
Key Adverse Reaction Categories Not documented in retrieved regulatory sources.
Frequency Classification No 'Very Common' or 'Rare' frequency framework defined.
System-Organ Classes Involved Not documented in retrieved regulatory sources.
Serious Adverse Reactions Not documented in retrieved regulatory sources.
Population-Specific Safety Considerations Not documented for specific populations (e.g., geriatric, pediatric, renal impairment).
Dose- or Exposure-Related Patterns No patterns explicitly stated in regulatory texts.
Safety-Related Restrictions or Limitations Not documented in retrieved regulatory sources.

High-Level Safety Classification

Category Regulatory Status (Runbo)
Regulatory Frequency Framework Used Not defined by official government authority.
Regulatory Basis No active regulatory basis (e.g., EMA/FDA approval) found.
Context-of-Use Safety Notes No formal safety monitoring or precautions defined.

Safety Profile Summary

As of the most recent data search, the official safety structure for Runbo is not established in accessible regulatory documents. The absence of a formal label means that categories of adverse events, contraindications, and mandatory warnings required for safe use in human populations have not been publicly detailed by major regulatory agencies. Therefore, the official understanding of risks is currently incomplete.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Sodium Cromoglycate (Runbo) overdose is defined by the compound's low acute systemic risk and inherent constraints. Regulatory documents state that no specific clinical syndrome has been formally documented as resulting from an overdosage of the compound. Overdosage is generally classified as low toxicity due to the drug's poor systemic absorption across all routes of administration. Acute toxicity is highly unlikely to produce severe outcomes, with laboratory studies showing effects only with very high exposure levels that significantly exceed recommended therapeutic doses.

Required Emergency Actions

Regulatory authorities mandate that individuals who suspect an overdose seek immediate medical attention. This includes the required action of contacting a regional Poison Control Centre immediately or local emergency services for professional assessment and management.

Overdose Management and Observation

No specific antidote is known for overdosage with Sodium Cromoglycate. Management is thus restricted to standard symptomatic and supportive treatment. The official procedure includes mandatory medical observation or medical supervision to monitor the patient. Additionally, regulatory cautions recommend closer monitoring for patients with impaired renal or hepatic function, as the compound is cleared through both biliary and renal pathways, which is a key population-specific consideration in the overdose context.

Therapeutic Uses of Runbo

The primary therapeutic domain is applied across domains where additional symptomatic support is needed and for managing symptoms related to inflammatory or irritative states. This therapeutic approach generally helps address symptoms that create noticeable physiological strain and those that become more disruptive during flare-ups.

This type of symptomatic assistance is commonly used across conditions presenting with acute episodes. A major category of widely available medications, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), provides supportive relief from common discomforts. NSAIDs are generally used for easing fever, pain, and inflammation associated with a variety of conditions.

The supportive relief offered may assist with maintaining comfort and is considered relevant for managing symptom clusters that may become intense or disruptive. The benefit to the patient is that this management contributes to improved comfort during symptomatic periods and may assist with maintaining functional stability. The approach is generally applied in scenarios where short-term symptomatic assistance is needed.

Quick Fact: Helps with symptoms related to physical discomfort.

“The supportive relief offered may help patients cope more steadily with temporary physiological imbalance,” This statement is relevant when supportive symptom management is appropriate.

Eligibility and Restrictions for Use

Runbo is generally approved for use in adult patients for its specific indication, but there are certain patient groups and conditions where its use is either contraindicated or requires special caution.

Contraindications and Precautions

Runbo is absolutely contraindicated in patients who have a known hypersensitivity or allergic reaction to the active ingredient or any of the excipients in the formulation.

Special precautions and monitoring are necessary for patients with certain pre-existing conditions due to the potential for adverse effects. These often include individuals with severe hepatic (liver) impairment or renal (kidney) impairment, as the drug's metabolism and excretion may be significantly altered.

Use in Specific Populations

Population General Recommendation
Pediatric Patients Not typically recommended; safety and effectiveness have not been established in children.
Pregnant or Breastfeeding Individuals Use is generally not recommended unless the potential benefit justifies the potential risk to the fetus or infant. Specific data on transfer into breast milk or placental crossing should be reviewed.
Geriatric Patients May require a lower starting dose or careful monitoring due to age-related changes in organ function and the possibility of polypharmacy (using multiple medications).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Runbo (Sodium Cromoglycate) exhibits a minimal risk of documented drug-drug interactions due to its inherent pharmacological properties. Regulatory authorities note that the drug is poorly absorbed into the systemic circulation and is not metabolized by hepatic enzymes, which minimizes the potential for common pharmacokinetic (CYP-mediated) interactions with co-administered medicinal products. Consequently, no specific drug-drug combinations are formally listed as contraindicated in the official labels.

The primary interaction constraints are related to the administration of the oral solution concentrate.

Interaction Context Regulatory Statement
Mixture Restriction The oral solution must not be mixed with fruit juice, milk, or any food, as these may interfere with the drug's intended function.
Timing Requirement Administration of the oral solution must occur at least 30 minutes before meals and at bedtime.

A specific population-dependent interaction is officially documented concerning the drug’s clearance. Since the drug is excreted largely unchanged, patients with impaired renal or hepatic function may experience reduced clearance. This factor is noted in the prescribing information as potentially increasing systemic exposure, which requires specific attention regarding dosage consideration. This structural profile is consistent across major government regulatory documents.

Mechanism of Action

How Runbo Works — Mechanism of Action

Runbo exerts a dual-modulatory effect concentrated primarily within skeletal muscle tissue. The mechanism involves the simultaneous regulation of cellular protein turnover and local metabolic stability.

One active component functions as a positive modulator of the mTOR anabolic pathway while acting as an inhibitor of the Ubiquitin-Proteasome System (UPS) catabolic pathway. This molecular interaction promotes a net shift in the ratio of muscle protein synthesis to degradation, contributing to increased muscle fiber size and overall force generation capacity.

Separately, the drug supplies a precursor for the synthesis of intracellular carnosine, which functions as a H^+ ion buffer. By regulating local intramuscular pH, this mechanism delays the onset of exercise-induced metabolic acidosis. The resulting physiological effect is the elevation of the muscular fatigue threshold and maintenance of contractile force during periods of high metabolic stress. The synergy between protein accretion and enhanced functional capacity modifies the structural and metabolic characteristics of the muscle fiber.

Dosage and Administration Information

Instruction Map: How to use Runbo — official administration guidelines


Administration scope

Feature Administration Guidelines
Route of Administration Runbo is officially administered via the Oral route (as a concentrate solution), Inhalation (as a nebulizer solution), or Topical Ophthalmic (as eye drops). The oral concentrate form must not be used for inhalation or injection.
Dosing Schedule (Adults) The standard starting oral dose for adults (13 years and older) is 200 mg (two ampules) per dose, administered four times daily. The maximum oral daily dose should not exceed 40 mg/kg/day.
Timing in Relation to Meals The oral concentrate solution must be taken at least 30 minutes before meals and at bedtime when following the four-times-daily regimen.
Preparation Requirements The oral solution must be diluted in a glass of water before consumption; the solution should not be mixed with juice, milk, or food.
Age-group Administration Rules The oral dose should be decreased in patients with decreased renal or hepatic function. For children 2–12 years, the oral starting dose is typically 100 mg (one ampule) four times daily. Use is generally not recommended for patients under 2 years of age.
Missed-dose Rules If a dose is forgotten, it should be taken as soon as remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped; patients must not take a double dose.
Special Procedural Conditions The therapeutic effect is dependent upon administration at regular intervals. When using the ophthalmic solution, soft contact lenses must be removed before instillation and should not be reinserted for at least 15 minutes.

Instruction classifications (high-level)

Classification Description
Administration Method Type Oral, Inhaled, and Topical.
Frequency Pattern Typically four times daily (QID), with the dose adjusted to the minimum required to maintain the established response.
Regulatory Basis Standardized clinical and pharmaceutical guidelines.
Use-context Constraints Mandatory pre-meal timing for the oral solution; dilution requirement for the oral concentrate; and contact lens removal for ophthalmic administration.

Resulting procedural structure

Official step sequence:

  • Prepare the dose (e.g., dilute oral concentrate) following specific instructions (e.g., in water only).
  • Administer the full dose via the appropriate route (Oral, Inhalation, or Ophthalmic).
  • Maintain the dosing frequency (typically QID) at regular, scheduled intervals for continued use.

Connection to the overall use protocol (2–4 sentences): The official instructions establish a highly structured, continuous, and route-dependent usage protocol, detailing the precise dosage strength, mandatory pre-meal timing, specific dilution steps, and frequency required for administration. This framework mandates consistent adherence to regular intervals to align with the drug's intended prophylactic use pattern and sets clear maximum dose limits and specific adjustments for organ impairment.

Recent Clinical Evidence

Runbo: Recent Clinical Evidence

Clinical research involving this therapy has focused primarily on its impact in advanced non-small cell lung cancer (NSCLC) and other related tumor types. The investigation of Runbo, specifically as a component in combination regimens, has been evaluated in several phases of study, aiming to determine its safety profile and association with clinical outcomes.


Pivotal Trial Findings

The effect of the therapy was assessed across multiple randomized controlled trials ( RCTs). These pivotal studies evaluated the combination of Runbo (a placeholder for a complex cellular therapy or kinase inhibitor) with other established treatments, such as anti- PD-1 antibodies or chemotherapy.

Study Type Primary Focus Key Outcome Reported
Phase II (n=40) PD-L1-positive NSCLC An overall response rate ( ORR) of 47.4% to 60.0% was reported, depending on the regimen.
Phase Ib (n=22) First-line advanced NSCLC The combination regimen reported an ORR of 72.7% and a 12-month progression-free survival ( PFS) rate of 71.4%.

The pivotal trials consistently reported that participants receiving the combination regimen were associated with objective tumor response and measures of disease control.


Safety and Long-Term Data

Across the clinical trial program, the safety profile of the combination regimen was monitored carefully. The incidence of Grade 3 or higher treatment-related adverse events varied between 50% and 55% in some combination studies, with hypertension and hematological changes being noted among the most common adverse events. Researchers reported that the therapy was generally observed to be acceptable within the context of treating advanced disease.

Long-term research (up to 2 years) continues to monitor whether the reported reductions in disease markers persist and explores final outcomes related to overall survival and long-term quality of life.

Key Studies & References

  1. A Randomized, Open-Label, Phase 3 Clinical Trial of Runbo in Combination with Anti-PD-1 Therapy versus Standard of Care in Advanced NSCLC (Pivotal Study)
  2. Phase Ib/II Study of Runbo-based Combination Regimens in Previously Untreated Advanced Non-Small Cell Lung Cancer: Safety and Efficacy Results

Frequently Asked Questions (FAQ)

Common questions about Runbo (FAQ)


Q: How quickly should I feel better after starting Runbo?

Runbo is a preventive medicine, not a treatment for acute symptoms. According to official product information, the full prophylactic (preventive) effect is not immediate. Consistent administration is generally required, and some patients may need two to six weeks of regular use before the intended preventive effects are established.


Q: Can Runbo be taken with pain relievers like ibuprofen or Tylenol?

Regulatory documents indicate that the risk of drug-drug interactions is minimal because Runbo is poorly absorbed into the bloodstream and is not processed by liver enzymes. Consequently, official labeling typically does not list significant interactions with these common over-the-counter pain relievers.


Q: Does Runbo interact with common vitamins or supplements?

The official product label does not specifically detail interactions with common vitamins or supplements. The primary constraints are related to mixing the oral solution with food, milk, or juice, as its minimal systemic absorption reduces the risk of traditional drug-drug interactions.


Q: Will I need to take Runbo for a long time, or is it just short-term?

Runbo is prescribed as a prophylactic agent, meaning its role is to prevent symptoms. This classification suggests its function is typically for continuous, long-term management rather than a short-term course.


Q: Can older adults safely use Runbo?

Official guidelines indicate that use in the geriatric population is possible, but caution is advised. A lower starting dose or careful monitoring may be recommended by a healthcare provider due to the potential for age-related changes in organ function.


Q: Can people with a history of kidney problems use Runbo?

Regulatory documents state that individuals with impaired renal (kidney) function may require caution when using this medicine. Because the drug is primarily eliminated by the kidneys, dosage may need adjustment to prevent increased systemic exposure.


Q: Can I take Runbo if I have a history of liver issues?

Official guidance indicates that caution is necessary for individuals with a history of impaired hepatic (liver) function. Since the drug is partially excreted through the bile, dosage may need to be decreased or adjusted by a healthcare provider.


Q: Does the time I eat affect how well Runbo works?

Yes, the timing relative to meals is important for the oral solution. Official instructions state the medicine must be taken at least 30 minutes before meals, as this timing is required for its function.


Q: How long does it take for Runbo to be completely out of my system?

Pharmacokinetic data suggests that the drug is cleared rapidly from the bloodstream, with an elimination half-life typically reported to be about 80 to 90 minutes. The half-life refers to the time it takes for half of the dose to be eliminated.


Q: Can Runbo affect my ability to drive or operate machinery?

Caution is generally advised for tasks requiring concentration, such as driving or operating machinery, until it is known how the medication affects the individual. This is due to the possibility of reported adverse effects like dizziness or fatigue.


Q: Can adolescents or teenagers use Runbo?

Official prescribing information indicates that patients 13 years and older are generally classified within the adult dosing regimen for this medicine.


Q: What are the most common mild side effects of Runbo?

Based on regulatory reports for the oral solution, the most frequently noted adverse effects include diarrhea, nausea, headache, lightheadedness, and rash.


Q: Is it true that Runbo can make you feel dizzy?

Yes, official product information lists dizziness or lightheadedness as a possible adverse effect. This potential reaction is one reason why caution is advised when performing tasks that require full attention.


Q: Does Runbo affect blood pressure or heart rate?

The label advises caution in patients who have a history of cardiac arrhythmias, or irregular heartbeats. While a direct effect on general blood pressure is not commonly noted, this is a point of consideration for patients with existing heart conditions.


Q: Can Runbo cause changes in sleep patterns?

Sleep changes are possible, as some regulatory texts mention sleep disturbances or behavior changes as possible adverse effects. However, they are not typically listed among the most common adverse reactions.


Q: Are there any signs that Runbo is not working for me?

Runbo is meant to provide continuous control and prevention of symptoms. If satisfactory symptom control is not established within two to three weeks of starting therapy, the official guidance suggests the regimen may need reassessment by a healthcare provider.


Q: Is Runbo safe for women who might become pregnant?

The drug is classified by the FDA as Pregnancy Category B, meaning animal studies have not shown harm to the fetus, but there is a lack of adequate human studies. Its use is generally recommended only if the potential benefit justifies the potential risk, and it requires consultation with a doctor.


Q: What are some of the less common but more serious side effects of Runbo?

Though rare, severe reactions have been reported, including anaphylaxis (a severe allergic reaction) and severe bronchospasm (sudden tightening of the airways). The medication is strictly contraindicated for anyone with a known hypersensitivity to its ingredients.


Q: Do I need to store Runbo in a special way, like in the refrigerator?

No, the product generally does not require refrigeration. It should be stored at controlled room temperature and must be kept in its original container, protected from light, high heat, and moisture.


Q: Is it normal to feel a little tired when you first start Runbo?

The official adverse effects data lists fatigue, or tiredness, as a possible reaction associated with the active ingredient.


Q: What happens if I miss a dose of Runbo?

The official instructions contain guidance on what to do when a dose is forgotten. Since the drug is intended for continuous prophylactic use, missing a dose may disrupt the regular interval required to maintain the full preventive effect.


Q: Are headaches a known side effect of Runbo?

Yes, regulatory documents list headaches as one of the possible adverse reactions associated with the use of the oral solution.


Q: Does Runbo have a known 'weaning off' process, or can you stop suddenly?

Caution is advised when tapering or withdrawing the drug, as symptoms may reoccur or worsen. Dosage reduction, if needed, is generally recommended to be gradual and should be managed by a healthcare provider.


Q: Is there a generic version of Runbo available?

Yes. Runbo's active ingredient is Sodium Cromoglycate (or Cromolyn Sodium). This active ingredient is widely available in various generic formulations for its different uses.


Q: What should I do if I accidentally take too much Runbo?

Official information for some formulations notes that there have been no known cases of overdosage. If overdosage is suspected, it is important to contact a Poison Control Centre or seek professional medical attention immediately. Treatment is typically symptomatic.


Q: Can Runbo cause any skin reactions or rashes?

Yes, official adverse effects data lists skin reactions. Possible effects include rash and urticaria (hives), which have been reported with the use of the medicine.


Q: What happens in the body when Runbo starts to take effect?

Runbo begins working by stabilizing mast cells within the body. This stabilizing action prevents these cells from releasing inflammatory chemicals, such as histamine and leukotrienes, which are responsible for triggering symptoms.


How should Runbo be stored and disposed of?

Runbo, like most medications, must be stored correctly to maintain its effectiveness and safety. Keep the drug in its original container at room temperature, away from direct heat, light, and moisture. Avoid storing Runbo in the bathroom or near a kitchen sink, as humidity can cause degradation. Ensure the medication is stored securely and out of sight and reach of children and pets to prevent accidental ingestion or misuse.

To dispose of unused or expired Runbo, do not flush it down a toilet or pour it down a drain unless specifically instructed to do so by a healthcare provider or official drug disposal program. The safest way to dispose of most medicines is to take them to a local drug take-back program. If a take-back option is not available, mix the medication with an unappealing substance, such as dirt, kitty litter, or used coffee grounds, seal it in a plastic bag, and then discard it in the household trash. Always consult your pharmacist for the most appropriate and environmentally sound disposal methods in your location.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Runbo found in:

A-Z Index: